Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Connect Biopharmaceuticals

Request full access

Connect Biopharmaceuticals, Ltd. is a clinical-stage company that discovers

Suzhou Shi, ChinaFounded 2012Biotech & Life Sciences

About Connect Biopharmaceuticals

Connect Biopharma is a global clinical-stage biopharmaceutical company focused on creating innovative therapies for chronic inflammatory diseases driven by T cell biology. The company operates in key markets including China, the United States, Australia, and Europe, leveraging its expertise in functional cellular assays with T cells to discover and develop potent drug candidates. Connect Biopharma's business model revolves around the internal design and ownership of small molecules and antibodies, which are then advanced through clinical trials. Revenue is generated through the development and potential commercialization of these therapies, targeting conditions such as atopic dermatitis. The company serves patients suffering from chronic inflammatory diseases, aiming to improve their quality of life through cutting-edge medical research and development.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
61.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Autoimmune, Inflammatory Diseases, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
PRIVATE PLACEMENT VCOther financing Mar 2026 $0 — Panacea Venture ↗
IPOOther financing Mar 2021 $191M $191M Undisclosed —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Connect Biopharmaceuticals website traffic

Latest recorded traffic for Connect Biopharmaceuticals is 2.9K monthly website visits, down 85.5% over the last three months.

Latest monthly visits2.9K 3-month web change-85.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Landos BiopharmaA clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease Ashtabula, United States Acquired — $87M $43M
Legacy HealthcareBiopharma developing innovative botanical drugs in supportive oncology care and dermatology Epalinges, Switzerland Operational
Can-Fite BioPharmaA biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities Petah Tikva, Israel Operational
Viela BioClinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases Gaithersburg, United States Acquired
Enlivex TherapeuticsEnlivex Therapeutics Ltd, a cell immunotherapy company, develops autologous and allogeneic drugs for the treatment of autoimmune and inflammatory conditions that involve overexpression or hyperexpression of cytokines Jerusalem, Israel Operational
Topas TherapeuticsHarnessing the liver’s natural immunology capabilities to address areas of major unmet medical need Hamburg, Germany Operational
Enthera PharmaceuticalsDeveloping first-in-class biologics for several underserved autoimmune conditions Milan, Italy Operational
CitryllDevelops therapeutics targeting the neutrophil extracellular trap (NET) pathway to treat inflammatory diseases, with its lead antibody, CIT-013, in clinical trials for rheumatoid arthritis and hidradenitis suppurativa Oss, Netherlands Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Connect Biopharmaceuticals in the Suzhou Shi ecosystem

Live from Dealroom

The Connect Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Cowin Capital

Series A3 investors entered at this stage

Series B and later3 investors entered at this stage

Other known investors1 additional known investor

  • Panacea Venture
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Suzhou Shi HQ
Book a demo for the full country breakdown

See Connect Biopharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.